Single-cell RNA sequencing reveals chemokine self-feeding of myeloma cells promotes extramedullary metastasis

Shuang Geng1,2, Jing Wang1, Xiannian Zhang1,2, Jia-jia Zhang3, Fan Wu1,2, Yuhong Pang1,2, Yuping Zhong3, Jianbin Wang4, Wenming Wang1, Xiaqing Lyu1,2, Yanyi Huang1,2 and Hongmei Jing1

1 Department of Hematology, Biodynamic Optical Imaging Center (BIOPIC) and Lymphoma Research Center, Third Hospital, Peking University, Beijing, China
2 Beijing Advanced Innovation Center for Genomics (ICG), School of Life Sciences, Peking-Tsinghua Center for Life Sciences, Peking University, Beijing, China
3 Department of Hematology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China
4 School of Life Sciences, Tsinghua-Peking Center for Life Sciences, Tsinghua University, Beijing, China

Correspondence
Y. Huang, Department of Hematology, Biodynamic Optical Imaging Center (BIOPIC) and Lymphoma Research Center, Third Hospital, Peking University, 5 Yiheyuan Road, Haidian District, Beijing 100084, China or H. Jing, Department of Hematology, Biodynamic Optical Imaging Center (BIOPIC) and Lymphoma Research Center, Third Hospital, Peking University, 49 North Garden Road, Haidian District, Beijing 100191, China
Tel: +86-10-62758323 (YH); +86-10-82266785 (HJ)
E-mails: yanyi@pku.edu.cn (YH); hongmeijing@bjmu.edu.cn (HJ)
Shuang Geng, Jing Wang, and Xiannian Zhang contributed equally to this work

(Received 19 June 2019, revised 18 September 2019, accepted 19 September 2019, available online 17 October 2019)
doi:10.1002/1873-3468.13623
Edited by Alfonso Valencia

Multiple myeloma (MM) is a malignant proliferation of monoclonal plasma cells that produce monoclonal immunoglobulins and is defined by the presence of 10% of clonal plasma cells (PCs) in the bone marrow or a biopsy-proven extramedullary plasmacytoma (EMP). MM remains an incurable disease, representing the...
second most common hematologic malignancy worldwide. Its incidence has been increasing in recent years [1,2]. MM often presents with hypercalcemia, renal function impairment, anemia, and osteolytic lesions [3,4]. Over the past decade, the median survival of myeloma patients has increased to 8 years. This remarkable improvement is mostly because of the use of high-dose therapy followed by autologous stem cell transplantation, in addition to the widespread incorporation of novel agents, including immunomodulatory drugs (thalidomide and lenalidomide) and proteasome inhibitors (bortezomib). MM is a heterogeneous entity; the overall survival (OS) time of MM ranges from several months to several years.

For most myeloma patients, the proliferation of PCs is restricted to the bone marrow. However, a subset of MM patients develops EMPs, defined by the presence of clonal PCs outside the bone marrow, which generally involve soft tissue, cortical bone, and centrum, and may be some of the most prominent clinical features of MM [5]. EMPs are present at the time of initial diagnosis in 9.6–19.6% of MM patients and develop during treatment in 6–20% patients [6,7]. MM patients with EMP invasion have a poor prognosis and are difficult to treat [5]. In such patients, late detection and delayed treatment can seriously diminish quality of life and can be life-threatening. Therefore, it is clinically important to optimize the detection of this entity.

To date, the mechanisms of extramedullary spread in MM are poorly understood. In one hypothetical model of EMP pathogenesis, metastatic myeloma cells initially exit the bone marrow, translocate into blood as clonal circulating plasma cells (cPCs), and finally settle in peripheral tissues and form an EMP [8–10]. However, the mechanistic evidence for this hypothesis is limited.

Here, we focused on the initial extramedullary translocation of myeloma cells from bone marrow into peripheral blood. The transcriptome can dynamically reflect intrinsic and environmental fluctuations [11,12]. We took transcriptome snapshots to provide insights into the translocation mechanism and applied single-cell RNA-seq to explore transcriptomic differences between myeloma cells in bone marrow (BMMCs) and peripheral cPCs in each EMP-positive patient. We found a consensus of upregulated auto-secretion of the chemokine CXCL12 in cPCs. This CXCL12 upregulation may contribute to the initial extramedullary translocation by evasion of CXCR4-dependent cell retention in bone marrow. Upregulation of another bone marrow retention chemokine, CXCL7, was previously published [13], further supporting the notion of chemokine auto-secretion relating to extramedullary translocation in myeloma.

Materials and methods

Patients

The participants were 11 patients with primarily untreated MM (median age: 58 years, range: 49–76 years) and 10 patients with EMP (median age: 64.5 years, range: 44–75 years). All patients were diagnosed according to the 2009 International Myeloma Working Group (IMWG) consensus criteria [14]. The patients enrolled in this study were hospitalized during the period of October 2014 to June 2015 at the Peking University Third Hospital and Beijing Chao-Yang Hospital. The end point of the analyses was OS, which was defined as the time from diagnosis to death (regardless of the cause) or date of the last follow-up evaluation.

All patients received combination chemotherapy regimens, including BAD (bortezomib, doxorubicin, dexamethasone), VCD (bortezomib, cyclophosphamide, dexamethasone), TD (thalidomide, dexamethasone), RD (lenalidomide, dexamethasone), RCD (lenalidomide, cyclophosphamide, dexamethasone), and DCEP (dexamethasone, cyclophosphamide, etoposide, cisplatin). Some patients received additional radiation therapy, surgical therapy, and autologous hematopoietic stem cell transplantation. Efficacy criteria for MM were defined according to International Myeloma Working Group (IMWG) consensus criteria for response and minimal residual disease assessment in MM [15]. This research was approved by the ethics committee of Peking University Third Hospital (IRB00006761-2016120). All patients provided written informed consent in accordance with the Declaration of Helsinki.

Sample collection and preparation

Typically, 4 mL bone marrow aspirate or peripheral blood was drawn from patients in a sterile manner. Peripheral blood mononuclear cells (PBMCs) and bone marrow cells were isolated by Ficoll-Paque Plus (GE Healthcare Biosciences, Pittsburgh, PA, USA). A 2-min lysis of RBC (red blood cell) was performed if necessary. Samples were passed through 30-μm nylon mesh to remove cell clumps. Filters were wetted with buffer before use. Purification of CD138+ plasma cells from the single-cell suspension was performed using human CD138 MACS MicroBeads (Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manufacturer’s instructions. Cell number was determined, and the cell suspension was centrifuged at 300 g for 10 min. The supernatant was aspirated, and the cell pellet was resuspended in 80 μL of buffer per 2 × 10^7 total cells. Then, 20 μL of CD138 MicroBeads per 2 × 10^7 total cells was added, and mixed well, and cells were incubated for

FEBS Letters 594 (2020) 452–465 © 2019 The Authors. FEBS Letters published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.
15 min in the a refrigerator (2–8 °C). Cells were washed by adding 1–2 mL of buffer per 2 × 10⁷ total cells and centrifuging at 300 g for 10 min. The supernatant was then aspirated, and up to 10⁶ cells were resuspended in 500 μL of buffer. The column was placed in the magnetic field of a MACS Separator, and the MS column was prepared by rinsing with 500 μL of buffer. Cell suspension was aspirated, and up to 10⁸ cells were resuspended in 500 μL of buffer. The column was washed three times with 500 μL of buffer, and total eluent was collected; this eluent is the unlabeled cell fraction. The column was removed from the separator and placed on a collection tube. Onto the column, 1 mL of buffer was pipetted and the magnetically labeled CD138⁺ cells were immediately flushed out by firmly pushing the plunger into the column. The single-cell suspension was then stained with antibodies and analyzed or sorted by flow cytometry.

**Flow cytometry**

Antibodies [CD38 clone HB-7, CD138 clone DL-101, CD117 (c-kit) clone 104D2, CD56 (N-CAM) clone 5.1H11, CD45 clone 2D1, CD19 clone HIB19] and cell viability dyes (Zombie NIR and Zombie Aqua) were purchased from BioLegend (San Diego, CA, USA). Antibodies and dyes were optimized for optimal performance. Compensation matrices were generated with Ultra CompBeads (eBioscience/Thermo Fisher, Carlsbad, CA, USA) and confirmed with samples. Data were collected with Aria II SORP flow cytometer (BD Biosciences, San Jose, CA, USA) and analyzed with FLOWJO (FlowJo LLC, Franklin Lakes, NJ, USA). Single cells were index-sorted into 96-well plates with the same machine.

**Single-cell RNA sequencing and analysis**

Single myeloma cells or cPCs were sorted into lysis buffer in 96-well plates with index sorting mode on FACS. The SmartSeq2 protocol was immediately performed to rescue mRNAs from cell lysate [16]. Libraries were constructed with a Tn5-based TruePrep DNA Library Prep Kit (Vazyme Biotech, Nanjing, China) and were sequenced on the HiSeq 2500 platform (Illumina, Inc., San Diego, CA, USA). Sequencing reads were aligned to the human reference genome GENCODE GRCh37 v25 transcriptome using SALMON v0.8.2 [17]. Cells with sufficient quality were selected (mitochondria reads < 20%, TPM > 1 genes over 1k). Thirty-two single BMMCs were prepared for every patient (Fig. 5); generally, > 50% cells passed QC.

Principal component analysis (PCA) was carried out using FactoMineR in R. Four hundred highly variable genes were selected from first four principal components (PCs). MM-related gene groups were chosen, and their loading value or score in PC1 and PC2 was plotted (Fig. 4C–E) and summarized (Fig. 4F,G). To explore the homogeneity and heterogeneity of myeloma among patients, 126 BM cells were analyzed by SEURAT (version 2.3.4: New York Genome Center, New York, NY, USA, default parameters) for highly variable genes and unsupervised hierarchical clustering (Fig. 5A). Selected gene groups were plotted in patient-oriented ordering (Fig. 5B–D). Selected gene groups were plotted in patient-oriented ordering (Fig. 5B–D, Fig. S3). To add unsupervised PCA, differential expression analysis between cPCs and BMMCs in the same patient was performed with DESeq2 and plotted in GRAPHPAD PRISM (Fig. 6C–E). Statistics of genes related to BM ingress, BM adhesion, and BM egress are summarized in Fig. 6F. The same analysis was performed for Fig. S5.

**Statistical analysis**

All calculations were performed using the Windows version of IBM SPSS software, version 18.0.1 (PASW Statistics for Windows; IBM, Armonk, NY, USA). OS and PFS were determined by the Kaplan–Meier analysis. Differences between survival curves were tested for statistical significance using two-tailed log-rank tests. Numerical data were analyzed by GRAPHPAD PRISM (GraphPad Software, Inc., La Jolla, CA, USA). Adjusted P-values were analyzed in R (R Core Team, Vienna, Austria). Nonparametric Mann–Whitney U-test was used for two-group comparisons in Fig. 1D. P < 0.05 (log-rank test) was considered statistically significant.

**Results**

**Circulating plasma cells worsen prognosis for EMP-positive patients**

Twenty-one MM patients were enrolled. In Table 1, clinical characteristic analysis is provided for the 10 EMP-positive and 11 EMP-negative patients. Compared with EMP⁺ patients, more EMP⁻ patients were female (80% versus 27.3%). There was an even distribution of immunoglobulin subtype, similar ISS stages, and higher ESR-LDH-ALB detection. EMP was located primarily in soft tissue, centrum, and the chest wall.

To explore the hypothesis that EMP occurrence might have been associated with BMMCs or cPCs, 19 bone marrow aspirate samples and 16 peripheral blood samples were successfully collected. Both BMMCs and cPCs expressed high levels of malignant activation marker CD38 and plasma cell marker CD138, as expected (Fig. S1). Consistent with MM diagnosis, BMMCs were positive in all 19 bone marrow aspirates, but there was no difference between EMP-positive and EMP-negative aspirate samples. cPCs were identified after MACS enrichment. Five out of 9 (55.5%) EMP-positive patients had detectable cPCs in
blood, whereas 2 out of 7 (28.6%) EMP-negative patients had detectable cPCs in blood (Fig. 1, Table 2). These results indicate that cPCs may be correlated with EMP progression from MM.

Circulating plasma cells have predictive power for survival of newly diagnosed MM[18]. However, it is still unknown whether cPCs contribute to EMP prognosis[19]. To address this issue, we first summarized OS of 21 patients. EMP-positive patients had significantly shorter survival than did EMP-negative patients (median survival: 12 months versus 74 months, \( P = 0.0002 \)). The same survival pattern was observed from retrospective data of 180 MM patients in our hospital during the period from 2008 to 2016 (median survival: 21 months versus 74 months, \( P = 0.0001 \)), suggesting minimal biased sampling of these 21 patients. In contrast, simply checking the presence of cPCs failed to predict survival in a significant way (\( P = 0.20 \)), whereas combining EMP and cPC information showed significant improvement in prognosis (\( P = 0.017 \)) (Fig. 2). EMP-negative patients showed maximal survival, regardless of cPCs presence. EMP-positive patients without cPCs in blood showed similar survival to 180 retrospective data with median survival of 21 months. However, EMP-positive patients with cPCs had extremely shortened median survival of 8 months, and all passed away within 2 years. Therefore, cPCs may provide a stratification insight for EMP as well as MM patients. Together, these results indicate that cPCs were more frequently detected in EMP-positive patients, and worsened their prognosis.

Circulating plasma cells showed a cluster differentiation marker phenotype similar to that of BM myeloma cells

Compared with normal plasma cells, myeloma cells dynamically regulate expression of surface cluster differentiation (CD) markers, such as down-regulation of B-cell markers CD45 and CD19, upregulation of adhesion molecules CD56 (N-CAM) and CD81, and variable regulation of tumorigenic marker CD117 (c-kit) [20]. As expected, BMMCs were
To explore the possibility that CD markers may contribute to cPCs’ exit from bone marrow, we compared cPCs with BMMCs in the same patient (P017 and P020 are EMP-positive; P013 is EMP-negative) (Table 2, Fig. 3). In general, CD markers were similarly expressed in both BMMCs and cPCs, and CD56 (N-CAM) was slightly downregulated in cPCs in P017 (BMMC 93800 to cPC 34100 in MFI, 2.8-fold) and P020 (BMMC 9093 to cPC 6524 in MFI, 1.4-fold), confirming existing reports of lower CD56 expression [20]. The finding that cPCs are similar to BMMCs in terms of surface CD markers does not help in understanding the extramedullary translocation. We then applied single-cell RNA-seq (scRNA-seq) to these cells, making effort to discover the major difference between cPCs and BMMCs through whole-transcriptome snapshots, overcoming limited marker space of immunophenotyping.

Single-cell RNA-seq identifies myeloma cells from normal cells

Each cell contains only a few pgRNAs, which are easy to degrade and sensitive to contaminations [21]. We used the SmartSeq2 protocol to capture and amplify single-cell transcriptomes for sequencing. SmartSeq2

### Table 1. Clinical characteristics of 21 patients with MM.

| Characteristics | MM | EMP(−) | EMP(+) |
|-----------------|----|--------|--------|
| Number          | 21 | 11     | 10     |
| Age             | 62 (44–76) | 58 (49–76) | 64.5 (44–75) |
| Gender          |     |        |        |
| Male            | 47.6% (10/21) | 72.7% (8/11) | 20.0% (2/10) |
| Female          | 52.4% (11/21) | 27.3% (3/11) | 80.0% (8/10) |
| M component at diagnosis | | | |
| Ig G            | 61.9% (13/21) | 54.5% (6/11) | 70.0% (7/10) |
| Ig A            | 28.6% (6/21) | 45.5% (5/11) | 10.0% (1/10) |
| Ig D            | 4.8% (1/21) | 0 | 10.0% (1/10) |
| Light chain     | 4.8% (1/21) | 0 | 10.0% (1/10) |
| Stage of ISS    |     |        |        |
| I               | 23.8% (5/21) | 18.2% (2/11) | 30.0% (3/10) |
| II              | 33.3% (7/21) | 27.3% (3/11) | 40.0% (4/10) |
| III             | 42.9% (9/21) | 54.5% (6/11) | 30.0% (3/10) |
| Anemia          | 71.4% (15/21) | 81.8% (9/11) | 60.0% (6/10) |
| ESR > 20 mm·h⁻¹ | 78.3% (16/21) | 62.6% (7/11) | 90.0% (9/10) |
| Hypercalcemia > 2.75 mmol·L⁻¹ | 9.5% (2/21) | 10.0% (1/10) |
| β2-MG > 1.8 mg·L⁻¹ | 14.3% (3/21) | 10.0% (1/10) |
| LDH > 245 U·L⁻¹ | 19.0% (4/21) | 30.0% (3/10) |
| CRP > 5 mg·L⁻¹ | 4.8% (1/21) | 0 | 10.0% (1/10) |
| ALB < 40 g·L⁻¹ | 78.3% (16/21) | 62.6% (7/11) | 90.0% (9/10) |

### Table 2. Sample collection and cell detection.

| Patient | BM collected | BMMC detected | PB collected | cPCs detected |
|---------|--------------|---------------|--------------|---------------|
| EMP+    |              |               |              |               |
| (n = 10) |              |               |              |               |
| P02     | +            | +             | +            | +             |
| P02     | +            | +             | +            | +             |
| P04     | +            | +             | +            | +             |
| P06     | +            | +             | +            | +             |
| P10     | +            | +             | +            | +             |
| P12     | +            | +             | +            | +             |
| P13     | +            | +             | +            | +             |
| P11     | +            | +             | +            | +             |
| P19     | +            | +             | +            | +             |
| P04     | +            | +             | N.C.         |               |
| P05     | +            | +             | N.C.         |               |
| P09     | +            | +             | N.C.         |               |
| P21     | +            | +             | N.C.         |               |
| EMP−    |              |               |              |               |
| (n = 11) |              |               |              |               |
| P01     | +            | +             | +            | +             |
| P06     | +            | +             | +            | +             |
| P10     | +            | +             | +            | +             |
| P12     | +            | +             | +            | +             |
| P08     | +            | +             | +            | +             |
| P13     | +            | +             | N.C.         |               |
| P04     | +            | +             | N.C.         |               |
| P07     | +            | +             | N.C.         |               |
| P09     | +            | +             | N.C.         |               |
| P21     | +            | +             | N.C.         |               |
| Total 21 | (BMCC detected/BM collected) % | (cPCs detected/PB collected) % | 100% (19/19) | EMP+ 55.5% (5/9) | EMP− 28.6% (2/7) |
has been shown to have high sensitivity, high reproducibility, and full-length profiling ability [16,22]. These features were confirmed by using MM cell lines H929 and U266 and observing high gene recovery, highly reproducible gene expression results, and high coverage and evenness across the gene body (Fig. S2).

Twenty-one out of 24 sequenced single CD38\(^+\)CD138\(^+\) BMMCs, with 5 out of 6 sequenced CD38\(^-\)CD138\(^-\) nonmyeloma control cells, were plotted. In PCA, PC1 (principal component 1) represented 22.6% of the total variance and provided separation between the two types of cells (Fig. 4A). The hierarchical clustering of the highly variable genes among cells showed that the two types of cells have distinct gene expression patterns and tend to cluster separately, as expected (Fig. 4B, Table S1).

We further validated several crucial gene groups for myeloma, including myeloma markers, essential signaling pathway proteins/transcription factors/growth factors, and tumorigenic genes. As expected, all genes strongly correlated with PC1 (loading value > 0.5) (Fig. 4C–E). Unsurprisingly, FACS markers, such as CD38, CD138, CD56, CD19, and CD117, also contributed to define BMMCs in the transcriptome, and CD45 negatively correlated with PC1, confirming CD45 downregulation in myeloma cells [18]. Interleukin-6 (IL-6) signaling molecules, including IL-6 signal transducer (IL6st), receptor (IL6R), and transcriptional factor STAT3, necessary for myeloma survival and progression [23–25], were upregulated in BMMCs and contribute to PC1. Transcriptional factors specific for myeloma cells, such as IRF4, Blimp-1 (PRDM1), and XBP1, are also transcribed in BMMCs [26–29]. Upregulation of nourishing growth factors for myeloma, such as HGF, IGF1, and VEGF [30–33], was also confirmed. Furthermore, tumorigenic genes correlated with PC1 [34–39] (Fig. 4F,G). Together, these results validate our scRNA-seq data for further explorations.

**Patient-oriented clustering of single BMMCs**

Next, we explored whether EMP patients have common traits in the single-cell transcriptome, which may in turn benefit EMP diagnosis or intervention. Single-cell analysis simultaneously monitors disease heterogeneity and homogeneity in multidimensional comparisons, such as between disease situations (EMP-positive or EMP-negative), between patients, and between single cells within the same patient. Therefore, to achieve a global view of myeloma, single-cell RNA-seq was performed on 126 single BMMCs from six patients (four EMP-positive, two EMP-negative), and hierarchical clustering of their highly variable genes was analyzed (Fig. S3, Table S2). The heat map depicts the structure of subgroups with both cells and their marker genes. In general, most of the cells clustered according to the patients. Each patient had a unique set of marker genes. Thus, no obvious similarity was observed among EMP-positive patients (P014, P017, P020, and P023) or between EMP-negative patients (P019 and P021). BMMCs clustered together within individual patients.

To further examine this patient-oriented clustering, single BMMCs were grouped and ordered by patient, and the expression levels of gene groups crucial for myeloma were checked. First, myeloma markers were confirmed. CD138 (SDC1), CD38, Blimp-1 (PRDM1), IRF4, XBP1, and IL-6R signaling genes (IL6R, IL6ST, and STAT3) were transcribed in BMMCs (Fig. 5A). Lack of CD117 (c-Kit, KIT) transcription confirmed our FACS observation that CD117 was rarely expressed on myeloma cells, regardless of EMP status. Expression of CD45 (PTPRC), CD19, and CD56 (NCAM1) was more dynamic, as expected, and patient-oriented.

We then analyzed the expression of immunoglobulin (Ig) genes, the hallmarks of clonal plasma cells. Constant regions of both Ig heavy chain (IGHG1 and IGHG2) and light chain (IGKC and IGLC1) were
Fig. 3. Circulating plasma cells were similar to BM myeloma cells on the surface. (A) Multifunctional immunophenotyping of BMMCs and cPCs. CD38^+CD138^+ single malignant plasma cells were stained with CD45, CD19, CD56, CD117, and CD81 simultaneously. (B) EMP^+ patient P017’s phenotype. (C) EMP^+ patient P020’s phenotype. (D) EMP^− patient P013’s phenotype. Data are shown in overlay. Negative populations were below 1000 MFI.
transcribed robustly (Fig. 5B). Variable regions of heavy chain (IGHV) and light chain (IGKV and IGLV) showed clonal expansion for individual patients. We observed that the variable regions were transcribed in a patient-specific way. For example, in patient P014, BMMCs transcribed heavy chain IGHV3-43 and light chain IGKV1-39. In P017, IGHV1-24 and IGKV1-39 were transcribed. In P019, clone-type was more heterogeneous as expression of IGHV3-43, IGKV1-39, and IGLV2-14 could be seen. In P020, major clone-types were IGHV3-33, IGKV1-33, and 3D-20. In P021, IGHV4-28, IGKV1-33, and 3D-20 were transcribed. In P023, most BMMCs transcribed only IGKV1-33. Thus, individual patients showed unique Ig origins, and single BMMCs were clonal in the same patients.

Growth factors were reported to feed myeloma progression through surface receptors [40]. Universal transcription of FGFRs (fibroblast growth factor receptor 3), HDGF (hepatoma-derived growth factor), IGF1 (insulin-like growth factors 1), and TNFRSF17 (B-cell
maturation antigen, BCMA) emphasized their values in myeloma diagnosis and intervention. Among these genes, we found no obvious differentiations between EMP-positive and EMP-negative patients (Fig. 5C).

Oncogenes and tumor suppressors are also relevant to myeloma progression, and we also observed patient-oriented clustering of single BMMCs (Fig. S4). We further compared our data with previously published gene expression profiles GEP92 [41] and GEP70 [42] using microarrays and confirmed that the gene expression of single BMMCs is highly patient-dependent (Fig. S5).

Abnormal chemokine auto-secretion may contribute to cPC extramedullary translocation from the bone marrow

As stated above, extramedullary translocation is the initial step of cPC egress from the bone marrow. To explore possible factors related to this translocation, we compared BMMCs and cPCs within the same patient (P017 and P020, both EMP-positive). In general, cPCs and BMMCs tended to cluster within the same cell type (Fig. 6A,B). Next, differentially expressed genes (DEG) were identified by DEG2 analysis, comparing cPCs to BMMCs. Then, shared DEGs of both EMP-positive patients were analyzed (Fig. 6C, Table S3). Interestingly, among shared genes, CXCL12 was identified, indicating its significance (Fig. 6D,E).

Chemokine CXCL12 and its sole receptor CXCR4 play pivotal roles in bone marrow cell retention [43,44]. CXCL12, functionally designated as stromal-derived factor-1 (SDF-1), is typically expressed in bone marrow stromal cells or vascular endothelial cells to attract CXCR4+ cells in bone marrow and brain [45–47], but is not expressed in immune cells, such as normal plasma cells. Therefore, this novel finding of abnormal...
CXCL12 transcription in cPCs may be utilized to circumvent CXCR4-dependent bone marrow retention.

Chemokine secretion utilizes a specific pathway, shown in Fig. 6F. With cPCs versus BMMCs, we found a global upregulation of secretion-related genes, including significantly over-expressed Rab11b in both P017 and P020. Furthermore, VAMP7, VAMP8, and Syntaxin-2/11 were upregulated in P017 cPCs, and SNX20 was upregulated in P020 cPCs (Fig. 6G). This upregulation of chemokine-secretive machinery in cPCs compared with BMMCs indicates robust CXCL12 auto-secretion.

As abnormal upregulation of chemokine CXCL12 expression in cPCs was found in both patients, this finding suggests a self-feed loop generated by cPCs, consequently releasing themselves from the CXCR4-dependent bone marrow retention and translocating freely into the circulation.

To further support this chemokine auto-secretion and self-feed notion, we incorporated analysis of a published
dataset. Pioneer genetic interrogation of cPCs at single-cell resolution has been reported [13]. Although no information about EMP diagnosis was provided, we can still compare the transcriptomes between cPCs and BMMCs across patients for common genes, as in Fig. 6. Both patients showed the distinction between cPCs and BMMCs by unsupervised clustering. Common genes in cPCs versus BMMCs were analyzed with the same significance criteria (FC > 10 and P < 10^{-5}). We found only one gene, CXCL7 (pro-platelet basic protein, PPBP), which was another bone marrow retention-related chemokine that is normally expressed by endothelial cells and platelets, but not by immune cells, including normal plasma cells (Fig. S6).

Although CXCL7's direct link to myeloma is unknown, it has been reported to be expressed in cancer cells [48]. Furthermore, its chemokine receptors CXCR1 and CXCR2 are related to bone marrow retention and extramedullary translocation of immune cells, such as neutrophils. Similar to CXCL12, the chemokine secretive pathway was upregulated for CXCL7 cells, such as neutrophils. Similar to CXCL12, the chemokine secretive pathway was upregulated for CXCL7 cells, such as neutrophils.

Conclusions

In summary, an abnormal chemokine auto-secretion was found to be upregulated specifically in cPCs. Both chemokines (CXCL12 and CXCL7) are strongly related to bone marrow retention and extramedullary translocation. Therefore, we deduce that a chemotactic self-feed mechanism may contribute to initial extramedullary translocation of cPCs from bone marrow, and the eventual formation of soft-tissue EMP. Our findings increase understanding of metastatic MM and identify a new chemokine target for intervention.

Acknowledgements

We are grateful to Dr Chunhong Zheng's expert critiques of this study. We appreciate Mr Zhonglin Fu and
Ms Fei Wang at the National Center for Protein Sciences Beijing (Peking University) for the assistance in flow cytometry experiments, and Dr Yun Zhang and her team at the Peking University High Throughput Sequencing Center for next-generation sequencing. The work was supported by the Natural Science Foundation of Beijing Municipality (7182178), China Health Promotion Foundation (CHPF-zlkysx-001), Ministry of Science and Technology of China (2016YFC0900100), National Natural Science Foundation of China (21327808, 21525521, and 21675098), Seed Fund of Medical Interdiscipline of Peking University (2014-ME-14), Beijing Advanced Innovation Center for Genomics, and the State Key Laboratory of Microbial Resources, Institute of Microbiology, Chinese Academy of Sciences.

Author contributions

SG, JW, YH, and HJ designed the study and prepared the manuscript. JW, JZ, YZ, and HJ contributed to patient enrollment and follow-up. SG, XL, and WW carried out single-cell RNA-seq analysis. XZ and FW carried out scRNA-seq data analysis. YP, JW, YH, and HJ critically reviewed the manuscript.

References

1 Becker N (2011) Epidemiology of multiple myeloma. Recent Results Cancer Res 183, 25–35.
2 Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A and Flowers CR (2016) 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin 66, 443–459.
3 Rajkumar SV (2015) Evolving diagnostic criteria for multiple myeloma. Hematology Am Soc Hematol Educ Program 2015, 272–278.
4 Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kaarstitis E, Richardson P et al. (2014) International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15, e538–e548.
5 Blade J, Fernandez de Larrea C, Rosinol L, Cibeira MT, Jimenez R and Powles R (2011) Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach. J Clin Oncol 29, 3805–3812.
6 Lu J, Lu J, Chen W, Huo Y, Huang X, Hou J and Chinese Medical Doctor Association Hematology Branch (2014) Clinical features and treatment outcome in newly diagnosed Chinese patients with multiple myeloma: results of a multicenter analysis. Blood Cancer J 4, e239.
7 Lee SE, Kim JH, Jeon YW, Yoon JH, Shin SH, Eom KS, Kim YJ, Kim HJ, Lee S, Cho SG et al. (2015) Impact of extramedullary plasmacytomas on outcomes according to treatment approach in newly diagnosed symptomatic multiple myeloma. Ann Hematol 94, 445–452.
8 Molica S (2012) Extramedullary involvement: an emerging problem in multiple myeloma. Clin Adv Hematol Oncol 10, 268–269.
9 Kakati BR, Krishna K, Krishna SG, Sharma SG, Sanathkumar N and Rego RF (2012) Extensive extramedullary disease involving the colon in multiple myeloma: a case report and review of literature. J Gastrointest Cancer 43, 379–381.
10 Blade J, de Larrea CF and Rosinol L (2012) Extramedullary involvement in multiple myeloma. Haematologica 97, 1618–1619.
11 Zhu Z, Li C, Yang S, Tian R, Wang J, Yuan Q, Dong H, He Z, Wang S and Li Z (2016) Dynamics of the transcriptome during human spermatogenesis: predicting the potential key genes regulating male gametes generation. Sci Rep 6, 19069.
12 Yang Y, Wang H, Chang KH, Qu H, Zhang Z, Xiong Q, Qi H, Cui P, Lin Q, Ruan X et al. (2013) Transcriptome dynamics during human erythroid differentiation and development. Genomics 102, 431–441.
13 Lohr JG, Kim S, Gould J, Knochel B, Drier Y, Cotton MJ, Gray D, Birrer N, Wong B, Ha G et al. (2016) Genetic interrogation of circulating multiple myeloma cells at single-cell resolution. Sci Transl Med 8, 363ra147.
14 Palumbo A, Sezer O, Kyle R, Miguel JS, Orlowski RZ, Moreau P, Niesvizky R, Morgan G, Comenzo R, Sonneveld P et al. (2009) International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia 23, 1716–1730.
15 Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, Munshi N, Lonial S, Bladé J, Mateos MV et al. (2016) International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17, e328–e346.
16 Picelli S, Faridani OR, Bjorklund AK, Winberg G, Sagasser S and Sandberg R (2014) Full-length RNA-seq from single cells using Smart-seq2. Nat Protoc 9, 171–181.
17 Patro R, Duggal G, Love MI, Irizarry RA and Kingsford C (2017) Salmon provides fast and bias-aware quantification of transcript expression. Nat Methods 14, 417–419.
18 Nowakowski GS, Witzig TE, Dingli D, Tracz MJ, Gertz MA, Lacy MQ, Lust JA, Dispenzieri A, Greipp
PR, Kyle RA et al. (2005) Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. Blood 106, 2276–2279.

19 Li J, Wang N, Tesfalual N, Gao X, Liu S and Yue B (2017) Prognostic value of circulating plasma cells in patients with multiple myeloma: a meta-analysis. PLoS One 12, e0181447.

20 Kumar S, Kimlinger T and Morice W (2010) Immunophenotyping in multiple myeloma and related plasma cell disorders. Best Pract Res Clin Haematol 23, 433–451.

21 Ramsköld D, Luo S, Wang YC, Li R, Deng Q, Faridani OR, Daniels GA, Khrebtukova I, Loring JF, Laurent LC et al. (2012) Full-length mRNA-Seq from single-cell levels of RNA and individual circulating tumor cells. Nat Biotechnol 30, 777–782.

22 Picelli S, Bjorklund AK, Faridani OR, Sagasser S, Winberg G and Sandberg R (2013) Smart-seq2 for sensitive full-length transcriptome profiling in single cells. Nat Methods 10, 1096–1098.

23 Mathes T, Manfro B, Zeller A, Dunand-Sauthier I, Bogen B and Huard B (2015) Autocrine amplification of immature myeloid cells by IL-6 in multiple myeloma-infiltrated bone marrow. Leukemia 29, 1882–1890.

24 Jernberg-Wiklund H, Pettersson M, Carlsson M and Shaffer AL, Emre NC, Lamy L, Ngo VN, Wright G, Xiao M, Eliscovich C, Eyras E, Real FX et al. (2011) Key contribution of CPEB4-mediated translational control to cancer progression. Nat Med 18, 83–90.

25 Suematsu S, Hibi M, Sugita T, Saito M, Murakami M, Matsusaka T, Matsuda T, Hirano T, Taga T and Kishimoto T (1990) Interleukin 6 (IL-6) and its receptor (IL-6R) in myeloma/plasmacytoma. Curr Top Microbiol Immunol 166, 13–22.

26 Shaffer AL, Emre NC, Lamy L, Ngo VN, Wright G, Xiao W, Powell J, Duve S, Yu X, Zhao H et al. (2008) IRF4 addiction in multiple myeloma. Nature 454, 226–231.

27 Borson ND, Lacy MQ and Wettstein PJ (2002) Altered mRNA expression of Pax5 and Blimp-1 in B cells in multiple myeloma. Blood 100, 4629–4639.

28 Mimura N, Fulciniti M, Gorgun G, Tai YT, Cirstea D, Santo L, Hu Y, Fabre C, Minami J, Ohguchi H et al. (2012) Blockade of XBP1 splicing by inhibition of IRE1alpha is a promising therapeutic option in multiple myeloma. Blood 119, 5772–5781.

29 Reimold AM, Iwakoshi NN, Manis J, Vallabhajosyula P, Szomolanyi-Tsuda E, Gravalles EM, Friend D, Grusby MJ, Alt F and Glimcher LH (2001) Plasma cell differentiation requires the transcription factor XBP-1. Nature 412, 300–307.

30 Freund GG, Kulas DT, Way BA and Mooney RA (1994) Functional insulin and insulin-like growth factor-1 receptors are preferentially expressed in multiple myeloma cell lines as compared to B-lymphoblastoid cell lines. Cancer Res 54, 3179–3185.

31 Borset M, Hjorth-Hansen H, Seidel C, Sundan A and Waage A (1996) Hepatocyte growth factor and its receptor c-met in multiple myeloma. Blood 88, 3998–4004.

32 Georgii-Hemming P, Wiklund HJ, Ljunggren O and Nilsson K (1996) Insulin-like growth factor I is a growth and survival factor in human multiple myeloma cell lines. Blood 88, 2250–2258.

33 Dankbar B, Padró T, Leo R, Feldmann B, Kropff M, Mesters RM, Serve H, Berdel WE and Kienast J (2000) Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 95, 2630–2636.

34 Ortiz-Zapater E, Pineda D, Martinez-Bosch N, Fernández-Miranda G, Iglesias M, Alameda F, Moreno M, Eliscovich C, Eyras E, Real FX et al. (2011) Key expression profiling of B lymphocytes and plasma cells from Waldenstrom’s macroglobulinemia: comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals. Leukemia 21, 541–549.

35 Daniel J and Liebau E (2014) The ufm1 cascade. Cells 3, 627–638.

36 Gutiérrez NC, Ocio EM, de Las Rivas J, Maiso P, Delgado M, Fernmín-A, Arcos MJ, Sánchez ML, Hernández JM and San Miguel JF (2007) Gene expression profiling of B lymphocytes and plasma cells from Waldenstrom’s macroglobulinemia: comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals. Leukemia 21, 541–549.

37 Daniel J and Liebau E (2014) The ufm1 cascade. Cells 3, 627–638.

38 Frigyesi I, Adolfsson J, Ali M, Christophersen MK, Johnsson E, Turesson I, Gullberg U, Hansson M and Nilsson B (2014) Robust isolation of malignant plasma cell lines as compared to B-lymphoblastoid cell lines. Blood 123, 1336–1340.

39 Teng Y, Gao M, Wang J, Kong Q, Hua H, Luo T and Jiang Y (2014) Inhibition of eIF2alpha dephosphorylation enhances TRAIL-induced apoptosis in hepatoma cells. Cell Death Dis 5, e1060.

40 Mahtouk K, Moreaux J, Hose D, Reme T, Meissner T, Jourdan M, Rossi JF, Pals ST, Goldschmidt H and Klein B (2010) Growth factors in multiple myeloma: a comprehensive analysis of their expression in tumor cells and bone marrow environment using Affymetrix microarrays. BMC Cancer 10, 198.

41 Kuiper R, Broyl A, de Knegt Y, van Vliet MH, van Beers EH, van der Holt B, el Jarari L, Mulligan G, Gregory W, Morgan G et al. (2012) A gene expression signature for high-risk multiple myeloma. Leukemia 26, 2406–2413.

42 Heuck CJ, Qu P, van Rhee F, Waheed S, Usmani SZ, Epstein J, Zhang Q, Edmondson R, Hoering A,
Crowley J et al. (2014) Five gene probes carry most of the discriminatory power of the 70-gene risk model in multiple myeloma. Leukemia 28, 2410–2413.

43 Beider K, Nagler A, Wald O, Franitza S, Dagan-Berger M, Wald H, Giladi H, Brocke S, Hanna J, Mandelboim O et al. (2003) Involvement of CXCR42 and IL-2 in the homing and retention of human NK and NK T cells to the bone marrow and spleen of NOD/SCID mice. Blood 102, 1951–1958.

44 Suratt BT, Petty JM, Young SK, Malcolm KC, Lieber JG, Nick JA, Gonzalo JA, Henson PM and Worthen GS (2004) Role of the CXCR43/SDF-1 chemokine axis in circulating neutrophil homeostasis. Blood 104, 565–571.

45 Pitt LA, Tikhonova AN, Hu H, Trimarchi T, King B, Gong Y, Sanchez-Martin M, Tsirigos A, Littman DR, Ferrando AA et al. (2015) CXCL12-producing vascular endothelial niches control acute T cell leukemia maintenance. Cancer Cell 27, 755–768.

46 Liu KK and Dorovini-Zis K (2009) Regulation of CXCL12 and CXCR45 expression by human brain endothelial cells and their role in CD4+ and CD8+ T cell adhesion and transendothelial migration. J Neuroimmunol 215, 49–64.

47 Schajnovitz A, Itkin T, D’Uva G, Kalinkovich A, Golan K, Ludin A, Cohen D, Shulman Z, Avigdor A, Nagler A et al. (2011) CXCL12 secretion by bone marrow stromal cells is dependent on cell contact and mediated by connexin-43 and connexin-45 gap junctions. Nat Immunol 12, 391–398.

48 Grépin R,Guyot M, Giuliano S, Boncompagni M, Ambrosetti D, Chamorey E, Scoazec JY, Negrier S, Simonnet H and Pages G (2014) The CXCL7/CXCR48/2 axis is a key driver in the growth of clear cell renal cell carcinoma. Cancer Res 74, 873–883.

49 Gonsalves WI, Rajkumar SV, Gupta V, Morice WG, Timm MM, Singh PP, Dispenzieri A, Buadi FK, Lacy MQ, Kapoor P et al. (2014) Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma. Leukemia 28, 2060–2065.

50 Ginsberg DM (1962) Circulating plasma cells in multiple myeloma. A method for detection and review of the problem. Ann Intern Med 57, 843–846.

51 Zandi M, Facon T, Preudhomme C, Canis F, Izydorczyk V, Llovi V, Hammad M, Bauters F and Cosson A (1994) Significance of circulating plasma cells in multiple myeloma. Leuk Lymphoma 14, 491–496.

52 Pecellina V, Janiulioniene A, Matuzeviciene R, Zvirblis T and Griskevicius L (2012) Circulating plasma cells predict the outcome of relapsed or refractory multiple myeloma. Leuk Lymphoma 53, 641–647.

53 Gonsalves WI, Morice WG, Rajkumar V, Gupta V, Timm MM, Dispenzieri A, Buadi FK, Lacy MQ, Singh PP, Kapoor P et al. (2014) Quantification of clonal circulating plasma cells in relapsed multiple myeloma. Br J Haematol 167, 500–505.

54 Kumar S, Rajkumar SV, Kyle RA, Lacy MQ, Dispenzieri A, Fonseca R, Lust JA, Gertz MA, Greipp PR and Witzig TE (2005) Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance. J Clin Oncol 23, 5668–5674.

Supporting information

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Fig. S1. Gating strategy of flow cytometry.

Fig. S2. Protocol validation.

Fig. S3. Patient-oriented clustering of BMSCs.

Fig. S4. Oncogenes, tumor suppressor genes supported patient-oriented clustering of BMSCs.

Fig. S5. Gene expression profile (GEP) genes supported patient-oriented clustering of BMSCs.

Fig. S6. CXCL7 were upregulated in cPCs compared with BMSCs in published data.

Table S1. PCA result for Fig. 4B.

Table S2. Seurat result for Fig. S3.

Table S3. DEG for Fig. 6C.